A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.

Timeline

Start

2026-07

Primary completion

2027-03

Completion

2027-07

Drugs

Indications